Liver Cirrhosis, Neutrophil Extracellular Trap Formation, Portal Vein Thrombosis
Conditions
Keywords
Neutrophil Extracellular Trap Formation, Portal Vein Thrombosis, Hypercoagulability
Brief summary
The aim of this study was to investigate whether NETs markers can enhance procoagulant activity and predict portal vein thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.So we recruit liver cirrhosis with portal vein thrombosis and without portal vein thrombosis treated at the Affiliated Hospital of Qingdao University and collection of blood samples.
Detailed description
Seventy-nine patients with benign liver cirrhosis treated at the Affiliated Hospital of Qingdao University (China) from September 2020 to January 2021 were recruited for this study, including 26 patients with portal vein thrombosis and 53 patients without portal vein thrombosis. NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits. T-test was performed to analyze whether there was a statistical difference between the two groups, and regression analysis was performed between NETs markers and tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I to investigate whether there was a correlation. This study without any intervention measures, will not cause harm.
Interventions
DIAGNOSTIC_TESTtest NETs markers
NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
Sponsors
The Affiliated Hospital of Qingdao University
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
（1) Clinical diagnosis of liver cirrhosis (2) Clinical diagnosis of portal vein thrombosis
Exclusion criteria
1. primary or secondary liver malignancy 2. hematologic diseases 3. Bud-Chiah syndrome 4. incomplete data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of NETs markers | 1 year. | NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits. |
Countries
China
Outcome results
None listed